Abstract
cNeT therapy addresses limitations of TIL therapies including the requirement for high dose lymphodepletion and IL-2 which restricts application to fitter patients, and limited understanding of the active component that limits product optimisation and potency assay development. We have initiated trials evaluating cNeT in advanced, heavily pre-treated patients with NSCLC (CHIRON, NCT04032847) or melanoma (THETIS, NCT03997474) utilising lower dose lymphodepletion and IL-2 (1M IU/m2 sc x10d).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
